Mass tort attorneys and their financial backers find themselves in a predicament as many significant cases continue to drag on without resolution, leaving them trapped in a cycle of debt. Two prominent multi-district personal injury cases exemplify this issue, each bogged down by legal complexities and procedural delays. Johnson & Johnson’s repeated bankruptcy filings have stalled an $8 billion settlement involving talc product cancer claims, while a judicial divide over Bayer’s pesticide, Roundup, may necessitate intervention by the U.S. Supreme Court. Altogether, these setbacks are having a significant financial impact on involved parties.
As these cases linger, high-interest loans used by law firms to sustain their operations and pursue litigation are maturing, forcing firms into the costly process of refinancing. Funders who once saw mass torts as lucrative opportunities now face pressures from limited partners for returns, and some legal enterprises are experiencing a liquidity crunch. Michael Kelley, a partner with Parker Poe, underscores the urgency of these looming loan maturity dates and the necessity for firms to revamp their loan structures.
The growing burden of debt has ushered in a wave of refinancing, with attorneys and law firms compelled to make concessions to lenders. These often include increased guarantees and operational budget cuts. Michael Papantonio from Levin Papantonio expressed concern over the financial ramifications for clients, asserting they suffer multiple times due to prolonged financing cycles.
The market has been flooded with new entrants aiming to capitalize on mass tort opportunities, leading to an environment perceived as overleveraged. Brian Roth of Rocade Capital describes the situation as a “digestion phase,” following an intense influx of capital. Jim Onder of OnderLaw predicts an oncoming wave of consolidation due to an overwhelming number of new players unfamiliar with the intricate risks of litigation funding. According to Onder, many lack the skills to pinpoint viable litigation opportunities, leading to imprudent investment decisions.
As they strategize for future cases, seasoned attorneys are focusing on litigation related to the contraceptive injection Depo-Provera, alleging Pfizer Inc. neglected to highlight the risks of brain tumors. The rising costs for case referrals for Depo-Provera lawsuits already reflect the competitive and financially demanding nature of identifying and pursuing these claims. Attorneys and funders alike are urged to more critically assess the landscape to avoid costly pitfalls as they pursue mass tort litigation in the years to come.